Phenylpiracetam (Phenotropil)

Tier 3 — weak evidence · Nootropic · Stimulant · Cold tolerance

A phenylated derivative of piracetam developed in Russia for cosmonauts to improve cold tolerance and cognitive performance under stress. Banned by WADA as a stimulant. Russian clinical trials report improved cognition, reduced anxiety, and enhanced cold resistance. Tolerance develops rapidly with daily use. Not approved outside Russia. Limited independent safety data.

Dose: 100–200 mg/day in 1–2 doses; tolerance develops within 1–2 weeks; cycle 2 weeks on, 2 weeks off